Comparative effectiveness and safety of five Janus kinase inhibitors in real-world clinical practice: the multicentre ANSWER cohort

Clicks: 9
ID: 337603
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #328 of 335 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 335 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: To compare treatment effectiveness and safety among five Janus kinase inhibitors (JAKi) in patients with rheumatoid arthritis (RA) and to identify factors associated with treatment discontinuation in real-world clinical practice. METHODS: This retrospective multicentre study used data from the ANSWER cohort in Japan. RA treatment courses initiating tofacitinib, baricitinib, peficitinib, upadacitinib, or filgotinib between 2013 and 2025 were included. Treatment discontinuation due to ineffectiveness and adverse events was evaluated using Kaplan-Meier analysis and multivariable Cox proportional hazards models with multiple imputation. Analyses were adjusted for patient, disease, and treatment characteristics, including prior treatment history. RESULTS: A total of 1,798 treatment courses from 1,240 patients were analysed. Discontinuation risk due to ineffectiveness was lower with upadacitinib (HR 0.33, 95% CI 0.24 to 0.47) and filgotinib (HR 0.59, 95% CI 0.42 to 0.85) than with tofacitinib (reference), baricitinib (HR 0.82, 95% CI 0.63 to 1.06), and peficitinib (HR 1.23, 95% CI 0.89 to 1.70). Differences in discontinuation due to adverse events were observed only between upadacitinib (HR 0.57, 95% CI 0.38 to 0.85) and peficitinib (reference). Prior IL-6i or JAKi use increased ineffectiveness-related discontinuation for tofacitinib, baricitinib, and peficitinib, but not upadacitinib (IL-6i/JAKi: HR 0.67/1.14, 95% CI 0.38-1.16/0.65-1.98) or filgotinib (HR 0.83/1.38, 95% CI 0.45-1.53/0.72-2.65). CONCLUSIONS: Treatment effectiveness and safety differed among JAKi in real-world clinical practice. Upadacitinib and filgotinib were associated with higher treatment persistence, and the adverse impact of prior IL-6 inhibitor or JAKi exposure was not evident for these agents.
Reference Key
openalex_W7224096128 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yuki Etani, Yasutaka Okita, Kohei Tsujimoto, Yuichi Maeda, So Kuroda, Takaaki Noguchi, Takayuki Fujii, Akira Ōnishi, Tadashi Okano, Motomu Hashimoto, Iku Shirasugi, Shinya Hayashi, Yuji Nozaki, Daisuke Tomita, Akihiro Tanaka, Hideki Amuro, Hideyuki Shiba, Mahiro Yamamoto, Masaki Katayama, Wataru Yamamoto, Atsushi Kumanogoh, Seiji Okada, Ken Nakata, Kosuke Ebina
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag605
URL
https://doi.org/10.1093/rheumatology/keag605
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.